Abcellera Biologics Inc is trading at $5.75 (5.7% up) following a new oncology collaboration with Jazz Pharmaceuticals.
- The agreement includes $56 million in upfront payments and options for additional milestone payments.
- The partnership focuses on discovering and developing next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers.
- Investors are reacting positively to the significant upfront economics and the expansion of the company's therapeutic pipeline.